Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results

About this update from Castle Biosciences, Inc.

[{"type":"image","alt":"Castle Biosciences, Inc.","displaySize":"","headline":null,"caption":"Castle Biosciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/2fd044d9f86d752b3eef3517a0e9eaa9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bA4bKTFeOaJHrrCyNIjctQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2fd044d9f86d752b3eef3517a0e9eaa9","width":300,"height":300}},"lazy":false},{"type":"text","content":"2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 37% over 2024","length":114,"tagName":"p"},{"type":"text","content":"Exceeded 2025 guidance with full-year revenue of $344 million","length":61,"tagName":"p"},{"type":"text","content":"Conference call and webcast today at 4:30 p.m. ET","length":49,"tagName":"p"},{"type":"text","content":"FRIENDSWOOD, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and year ended Dec. 31, 2025.“We closed out an outstanding year with a strong fourth quarter, reflecting the strength of our innovative test portfolio, disciplined execution and the dedication of the entire Castle team who continue to deliver meaningful impact for patients and clinicians every day,” said Derek Maetzold, president and chief executive officer of Castle Biosciences. “We exited 2025 with clear leadership across our core dermatologic and gastrointestinal franchises, highlighted by continued momentum in TissueCypher, which achieved 86% test report growth over 2024.","length":817,"tagName":"p"},{"type":"text","content":"“In 2025, we also delivered an important milestone with the limited access launch of AdvanceAD-Tx™, which materially expanded our total addressable market and reinforced our commitment to providing clinical answers to dermatology clinicians and their patients. As we look ahead to 2026 and beyond, we believe we are well positioned to continue delivering stockholder value and capitalize on our near- and long-term opportunities, supported by continued test adoption growth for our core tests, a robust pipeline and a strong balance sheet.”","length":540,"tagName":"p"}...

More updates from Castle Biosciences, Inc.